Clinical Trials Directory

Trials / Unknown

UnknownNCT05001204

68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Peking Union Medical College Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in Gastrointestinal stromal tumor（GIST）patients. A single dose of 55.5 to 148 MBq(1.5-4 mCi) of 68Ga-NOTA-RM26 will be injected intravenously. Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection.

Detailed description

Rm26 is a bioactive polypeptide containing 9 amino acid residues, which can specifically bind to gastrin releasing peptide receptor (GRPR, BB2 receptor). Previous studies have confirmed that there are a large number of GRPR receptors in human common types of tumors, such as lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, glioma and gastrointestinal tumors. Therefore, the use of various radionuclide labeled gastrin releasing peptide receptor analogues RM26 for tumor targeted imaging and treatment greatly improves the early detection rate of tumor, and has important clinical significance and value in tumor staging, prognosis evaluation and curative effect evaluation.This prospective pilot study investigated the use of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR), for evaluating breast cancer using positron-emission tomography/computed tomography (PET/CT).

Conditions

Interventions

TypeNameDescription
DRUG68Ga-NOTA-RM2668Ga-NOTA-RM26 were injected into the patients before the PET/CT scans

Timeline

Start date
2021-05-01
Primary completion
2022-08-31
Completion
2022-08-31
First posted
2021-08-11
Last updated
2021-08-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05001204. Inclusion in this directory is not an endorsement.